Sheri A - Search Results

1

Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.

Noujaim J, Thway K, Sheri A, Keller C, Jones RL. Noujaim J, et al. Among authors: sheri a. Int J Surg Pathol. 2016 Feb;24(1):5-15. doi: 10.1177/1066896915606971. Epub 2015 Sep 22. Int J Surg Pathol. 2016. PMID: 26399578 Review.

2

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M. Sheri A, et al. Among authors: a hern r. Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361988 Free article.

3

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M. Sheri A, et al. Breast Cancer Res Treat. 2017 Jul;164(2):395-400. doi: 10.1007/s10549-017-4266-9. Epub 2017 Apr 26. Breast Cancer Res Treat. 2017. PMID: 28447240 Free PMC article.

4

New developments and future directions in systemic therapy.

Sheri A, Johnston S. Sheri A, et al. Clin Oncol (R Coll Radiol). 2013 Feb;25(2):117-26. doi: 10.1016/j.clon.2012.10.007. Epub 2012 Dec 6. Clin Oncol (R Coll Radiol). 2013. PMID: 23219233 Review.

5

Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.

Sheri A, Dowsett M. Sheri A, et al. Ann Oncol. 2012 Sep;23 Suppl 10:x219-27. doi: 10.1093/annonc/mds307. Ann Oncol. 2012. PMID: 22987966 Free article.

6

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.

Klintman M, Buus R, Cheang MC, Sheri A, Smith IE, Dowsett M. Klintman M, et al. Among authors: sheri a. Clin Cancer Res. 2016 May 15;22(10):2405-16. doi: 10.1158/1078-0432.CCR-15-1488. Clin Cancer Res. 2016. PMID: 27179111

7

Predicting response to cytotoxic drugs--the endocrine part of the story.

Sheri A, Dowsett M. Sheri A, et al. Breast. 2011 Oct;20 Suppl 3:S28-30. doi: 10.1016/S0960-9776(11)70290-9. Breast. 2011. PMID: 22015289 Free article. Review.

8

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson A, Okonji D, Assersohn L, Rigg A, Sheri A, Turner N, Smith I, Parton M, Dowsett M. Dodson A, et al. Among authors: sheri a. Breast Cancer Res Treat. 2018 Feb;168(1):249-258. doi: 10.1007/s10549-017-4514-z. Epub 2017 Nov 11. Breast Cancer Res Treat. 2018. PMID: 29128896 Free PMC article.

9

Is capecitabine efficacious in triple negative metastatic breast cancer?

Kotsori AA, Dolly S, Sheri A, Parton M, Shaunak N, Ashley S, Walsh G, Johnston S, Smith IE. Kotsori AA, et al. Among authors: sheri a. Oncology. 2010;79(5-6):331-6. doi: 10.1159/000323175. Epub 2011 Mar 23. Oncology. 2010. PMID: 21430400

10

Targeting endocrine resistance: is there a role for mTOR inhibition?

Sheri A, Martin LA, Johnston S. Sheri A, et al. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S79-85. doi: 10.3816/CBC.2010.s.016. Clin Breast Cancer. 2010. PMID: 21115426 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters